Stately Bio: $12 Million Closed For Developing Regenerative Medicines With Cellular Imaging Platform
Stately Bio, a company developing cell therapies using an ML-based live-cell imaging platform, announced $12 million in seed funding led by AIX Ventures, with participation from Dimension Capital, ...
Generation Bio announces new programs using ctLNP for targeted siRNA delivery in T cell-driven autoimmune diseases, aiming for IND submission in 2026. Development of novel siRNA therapeutics using ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results